AAV Manufacturing Solutions
Industry leading technologies and services
OXGENE's transient AAV production system and revolutionary new TESSA™ technology build on our considerable expertise in cell line development and plasmid engineering. Based on our widely recognised SnapFast™ plasmid technology, our transient production system facilitates high quality, high-titre AAV production, while our scalable TESSA™ technology offers a plasmid free alternative for large scale clinical manufacture. Our GMP banked clonal, suspension HEK293 cell line has been carefully developed to maximise rAAV yield.
We offer expert cloning and engineering services to optimise expression of your gene of interest. Our process development services optimise for pre-clinical rAAV manufacture in our ISO:9001 accredited lab, and we manufacture up to 10L scale, before assisting technology transfer to your own facilities or CMO.
Transient AAV production
Our reconfigured Rep-Cap plasmid, modified Ad5 helper and GMP banked clonal suspension HEK293 cell line offer gene therapy pioneers improved AAV quality and yield.
TESSA™: scalable AAV production
Our proprietary Tet-enabled self silencing adenoviral (TESSA™) AAV manufacturing system delivers gene therapy pioneers high-yield, high quality AAV in a scalable, contaminant, chemical and transfection free process.
We know that as gene therapy pioneers, you need complete confidence in the performance of our technologies once they're transferred to your own facilities. That's why our scientists speak directly to yours, offering ongoing and comprehensive technical support.